Galectin Therapeutics (GALT) director awarded options on 60,000 shares

Rhea-AI Filing Summary

Galectin Therapeutics director Kevin D. Freeman reported a new stock option award. On January 16, 2026, he was granted a stock option (right to buy) covering 60,000 shares of Galectin Therapeutics common stock at an exercise price of $3.04 per share.

The option was issued under the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan and will vest 100% on December 31, 2026. Following this grant, Freeman beneficially owns 60,000 derivative securities directly in the form of these stock options.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

FREEMAN KEVIN D

(Last) (First) (Middle)

4960 PEACHTREE INDUSTRIAL BLVD

SUITE 240

(Street)

NORCROSS GA 30071

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
GALECTIN THERAPEUTICS INC [ GALT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/16/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)(1)	$3.04	01/16/2026		A		60,000		(2)	01/16/2036	Common Stock	60,000	$0	60,000	D

Explanation of Responses:

1. The stock options were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan.

2. The options vest 100% on December 31, 2026.

	Jack W. Callicutt, by power of attorney	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Galectin Therapeutics (GALT) report for Kevin D. Freeman?

Galectin Therapeutics reported that director Kevin D. Freeman received a grant of stock options on January 16, 2026. The award covers 60,000 shares of Galectin Therapeutics common stock in the form of a stock option (right to buy).

How many Galectin Therapeutics (GALT) shares are covered by Kevin D. Freeman’s option grant?

The stock option granted to Kevin D. Freeman covers 60,000 shares of Galectin Therapeutics common stock. After this grant, he beneficially owns 60,000 derivative securities directly in the form of these options.

What is the exercise price of Kevin D. Freeman’s Galectin Therapeutics (GALT) stock options?

The stock option granted to Kevin D. Freeman has an exercise price of $3.04 per share for the underlying Galectin Therapeutics common stock.

When do Kevin D. Freeman’s Galectin Therapeutics (GALT) options vest?

According to the disclosure, the options granted to Kevin D. Freeman vest 100% on December 31, 2026. There is no partial or incremental vesting schedule mentioned.

Under which plan were Kevin D. Freeman’s Galectin Therapeutics (GALT) options issued?

The stock options granted to Kevin D. Freeman were issued pursuant to the Galectin Therapeutics, Inc. 2019 Omnibus Equity Incentive Plan, as stated in the footnotes.

Is Kevin D. Freeman’s Galectin Therapeutics (GALT) option grant a direct or indirect holding?

The filing indicates that the 60,000 stock options are held directly by Kevin D. Freeman, with the ownership form reported as Direct (D).